Eli Lilly and Company (LLY)
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly's revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the double digits in the latest quarter.
Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab, the second FDA-approved Alzheimer's treatment on the market. It is too soon to know what kind of impact Lilly's Donanemab will have on future earnings, but I predict it will be fairly positive. Eli Lilly has proven its commitment to product depth and innovation, one of the many reasons it's the largest holding at my firm.
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.
Here's Why Eli Lilly Will Likely Announce a Stock Split
24/7 Wall Street Insights Unlike the declining stocks of some of its pharmaceutical rivals, Eli Lilly has continually beat analysts' forecasts and prospered accordingly.
Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer's Drug
Eli Lilly (NYSE: LLY ) stock is continuing a recent rally over the last year as a Food and Drug Administration (FDA) panel signs off on its Alzheimer's drug. The FDA panel voted unanimously in favor of Eli Lilly's donanemab in a recent meeting.
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.
FDA Nudge Sends Pharma Stock to Fresh Record Highs
Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved the pharmaceutical company's Alzheimer's drug, donanemab.
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
Lilly's current product lineup includes multiple growth drivers, including Mounjaro and Zepbound. The company's pipeline also features promising candidates, with two currently awaiting regulatory approvals.
Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab
Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical giant's Alzheimer's drug donanemab, increasing the likelihood of its approval in the U.S. later this year.
